Business
Syndax Pharmaceuticals Announces Appointment of Kate Madigan, M.D., as Chief Medical Officer
WALTHAM, Mass., March 1, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage
About this update from Syndax Pharmaceuticals, Inc.
[{"type":"text","content":"WALTHAM, Mass., March 1, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (\"Syndax,\" the \"Company\" or \"we\") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the appointment of Kate Madigan, M.D., to the role of Chief Medical Officer, effective immediately. Dr. Madigan, who brings to Syndax over 20 years of clinical hematology expertise and broad experience in the design and execution of early to late-stage clinical programs across oncology and rare diseases, will lead the Company's clinical development strategy. She will succeed Michael Meyers, M.D., Ph.D., who will continue with the Company through June before transitioning to serve in a consulting capacity. \n\"Dr. Madigan has a proven track record of driving the design and execution of late-stage clinical programs,\" said Briggs W. Morrison, M.D., President, Head of Research and Development at Syndax. \"Her demonstrated acumen in oncology development in both the academic and industry settings will be invaluable as we continue to expand our pipeline. Her appointment is the result of a thorough succession planning process as we lay the groundwork for our evolution into a fully-integrated oncology company. I would like to thank Dr. Meyers for his dedication to Syndax over the years, having played an essential role in advancing both SNDX-5613 and axatilimab from Investigational New Drug filing to the pivotal stage. We look forward to his continued contributions as we work to bring innovative cancer therapies to patients in areas of high unmet need.\"\n\"With two ongoing pivotal programs for two first-in-class and potentially best-in-class medicines and subsequent U.S. Food and Drug Administration filings expected next year, Syndax is well positioned to make a meaningful impact in the treatment of some of the most underserved therapeutic areas,\" said Dr. Madigan. \"The talented team at Syndax has already made impressive progress advancing the pipeline, and I look forward to building on that momentum to further advance the mission of realizing a future in which people with cancer live longer and better than ever before.\" \nDr. Madigan most recently served as Vice President, Head of Clinical Development at Syros Pharmaceuticals, where she oversaw the development and execution of clinical strate...